De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AmCad BioMed Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yi-Li Lee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	1.4yrs

Recente managementupdates

Recent updates

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

CEO

Yi-Li Lee

no data

Tenure

NT$146,000

Compensatie

Ms. Yi-Li Lee serves as Chairman and President at AmCad BioMed Corporation. She serves as Vice President of Credit Agricole Corporate and Investment Bank. Ms. Lee serves as Senior Deputy General Manager of...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yi-Li Lee	Chairman & President	no data	NT$146.00k	geen gegevens
Chen-Chia Lee	Director	no data	geen gegevens	geen gegevens
Yujia Li	Supervisor	no data	NT$45.00k	geen gegevens
Jinjian Zhang	Supervisor	no data	NT$45.00k	4.58% NT$ 65.0m
Junheng Liao	Supervisor	no data	NT$25.00k	geen gegevens
Weng-Foung Huang	Independent Director	no data	geen gegevens	geen gegevens
Yi-Ling Lee	Vice Chairman	3.9yrs	geen gegevens	geen gegevens
Tsay-Ping Wang	Director	1.4yrs	geen gegevens	geen gegevens
She-Yi Lin	Independent Director	1.4yrs	geen gegevens	geen gegevens
Hsueh-Yu Li	Independent Director	1.4yrs	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 4188 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw bestuur.

AmCad BioMed Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.24 loss in 2Q 2023)

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation to Report Q2, 2024 Results on Aug 08, 2024

AmCad BioMed Corporation has completed a Follow-on Equity Offering in the amount of TWD 230 million.

First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.20 loss in 1Q 2023)

AmCad BioMed Corporation has filed a Follow-on Equity Offering in the amount of TWD 350 million.

AmCad BioMed Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$0.85 loss per share (vs NT$1.01 loss in FY 2022)

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.24 loss per share (vs NT$0.22 loss in 2Q 2022)

New minor risk - Share price stability

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.27 loss per share (vs NT$0.001 profit in 3Q 2021)

Second quarter 2022 earnings released: NT$0.22 loss per share (vs NT$0.16 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.15 loss per share (vs NT$0.21 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

AmCad BioMed Corporation Appoints Maureen Chang as Spokesperson, Financial Officer and Accounting Officer

Third quarter 2021 earnings released: EPS NT$0.001 (vs NT$0.18 loss in 3Q 2020)

AmCad BioMed Corporation Announces Receiving FDA Approval of AmCad UTdeep Learning Advanced Version

Second quarter 2021 earnings released: NT$0.16 loss per share (vs NT$0.10 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.21 loss per share (vs NT$0.30 loss in 1Q 2020)

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

AmCad BioMed Corporation, Annual General Meeting, May 21, 2021

New 90-day low: NT$18.55

New 90-day low: NT$18.80

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Third quarter 2020 earnings released: NT$0.19 loss per share

AmCad BioMed Corporation Announces Board Changes

AmCad BioMed Corporation Announces Resignation of Lee, Chen Chia as Chairperson, Effective November 5, 2020

New 90-day low: NT$19.45

First half earnings released

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur